Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and continuing a faster-than-expected drug launch.
Rezdiffra sales reached $137 million for the quarter, beating consensus analyst estimates by more than $20 million and continuing a faster-than-expected drug launch.
